Business Standard

Teva Pharmaceutical's Q2 profit tops forecast, reaffirms 2020 outlook

The company also released with Regeneron Pharmaceuticals results for advanced trials for pain medication fasinumab

Teva Pharma
Premium

The logo of Teva Pharmaceutical Industries. Photo: Reuters

Reuters Tel Aviv
Teva Pharmaceutical Industries' quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis.
 
The company also released with Regeneron Pharmaceuticals results for advanced trials for pain medication fasinumab. They said primary endpoints were achieved with a 1 mg monthly dose, demonstrating "significant improvements in pain and physical function over placebo at week 16 and week 24".
 
Teva CEO Kare Schultz said the companies were still waiting for more safety data.
 
"Assuming that we get good long-term data that we will be reporting probably in the beginning of next

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in